Clinical Scorecard: Multisystem Inflammatory Syndrome in Children: Assessment, Treatment Strategies, and Prognosis
At a Glance
Category
Detail
Condition
Multisystem inflammatory syndrome in children (MIS-C), a postinfectious hyperinflammatory disorder following COVID-19 infection
Key Mechanisms
Postinfectious immune dysregulation causing systemic inflammation involving cardiac, gastrointestinal, neurologic, and hematologic systems
Target Population
Pediatric patients, typically under 21 years of age, occurring 2 to 6 weeks after SARS-CoV-2 infection or exposure
Care Setting
Hospital and specialized pediatric care settings with capacity for hemodynamic stabilization and immunomodulatory therapy
Key Highlights
MIS-C presents with persistent fever (>38.0°C for >24 hours), shock, and multisystem involvement (≥2 organs) with elevated inflammatory markers.
Management includes supportive care, immunomodulation with intravenous immunoglobulin (IVIG), corticosteroids, biologics, and thromboprophylaxis.
Mortality ranges from 1% to 2%, with most patients recovering fully with timely treatment; long-term follow-up is essential for cardiac and other complications.
Guideline-Based Recommendations
Diagnosis
Diagnosis requires fever, laboratory evidence of inflammation (elevated CRP, ferritin, D-dimer, ESR), and multisystem involvement without alternative diagnosis.
Diagnostic criteria from CDC and RCPCH emphasize prior SARS-CoV-2 infection or exposure within 2 to 6 weeks.
Differentiate MIS-C from similar inflammatory conditions such as Kawasaki disease, sepsis, and microbial infections.
Management
Acute-phase management centers on supportive care and hemodynamic stabilization.
Immunomodulatory therapy with intravenous immunoglobulin, corticosteroids, and biologic agents forms the therapeutic cornerstone.
Thromboprophylaxis is frequently warranted due to elevated thromboembolic risk.
Extracorporeal membrane oxygenation (ECMO) may be considered in refractory cardiorespiratory failure.
Monitoring & Follow-up
Long-term follow-up is essential to monitor for cardiac, gastrointestinal, and neurologic complications.
Postrecovery vaccination protocols should be considered.
Continuous assessment of inflammatory markers and organ function during hospitalization.
Risks
Potential for severe cardiovascular involvement including shock and cardiac dysfunction.
Risk of thromboembolic events necessitating thromboprophylaxis.
Diagnostic ambiguity due to overlap with other inflammatory syndromes.
Patient & Prescribing Data
Children and adolescents diagnosed with MIS-C following SARS-CoV-2 infection
Timely initiation of immunomodulatory therapy (IVIG, corticosteroids, biologics) improves outcomes; thromboprophylaxis is important due to hypercoagulability; ECMO reserved for severe refractory cases.
Clinical Best Practices
Early recognition and differentiation of MIS-C from other inflammatory conditions to initiate prompt treatment.
Use of standardized diagnostic criteria incorporating clinical and laboratory findings.
Multidisciplinary approach including pediatric infectious disease, cardiology, rheumatology, and critical care specialists.
Close monitoring for cardiac and other organ involvement during acute illness and recovery.
Implementation of thromboprophylaxis protocols tailored to patient risk.
Consideration of ECMO in cases of refractory cardiorespiratory failure.
